Pfizer announced a deal yesterday valued at as much as $725 million to develop and market an experimental treatment for Alzheimer’s disease. The deal with Medivation, a San Francisco biotechnology company, gives Pfizer a potentially novel degenerative disease therapy as…

Originally posted here:
Pfizer makes Alzheimer’s drug deal